Literature DB >> 20717914

Polysomnographic characteristics in patients with mucopolysaccharidoses.

Hsiang-Yu Lin1, Ming-Ren Chen, Ching-Chi Lin, Chih-Ping Chen, Dar-Shong Lin, Chih-Kuang Chuang, Dau-Ming Niu, Jui-Hung Chang, Hung-Chang Lee, Shuan-Pei Lin.   

Abstract

To evaluate the prevalence of obstructive sleep apnea (OSA) and to clarify sleep characteristics in patients with mucopolysaccharidoses (MPS), we performed overnight polysomnographic studies in 24 patients (22 males and 2 females; 3 with MPS I, 15 with MPS II, 1 with MPS III, 1 with MPS IV, and 4 with MPS VI; mean age, 10.8 ± 6.0 years; age range, 2.0-23.7 years; 2 patients ≥18 years of age). The nadir arterial oxygen saturation (SaO(2) ) was 74.5 ± 12.3%, and the average percentage of sleep time with an SaO(2) of <95% was 39.4%. The percentages of total sleep time spent in sleep stages N1, N2, N3, and R were 18.6 ± 10.8%, 50.3 ± 7.6%, 14.8 ± 8.1%, and 15.3 ± 4.6%, respectively. The respiratory disturbance index (RDI) was 21.8 ± 20.4/hr, and obstructive apnea-hypopnea index (OAHI) and central apnea index were 21.4 ± 19.9/hr and 0.4 ± 0.6/hr, respectively. The desaturation index was 17.6 ± 17.8/hr. All patients had some degree of OSA. For 22 children, the disorder was mild (OAHI 1.5-5) in 2, moderate (OAHI 5-10) in 7, and severe (OAHI > 10) in 13. Two patients with MPS II who received enzyme replacement therapy had reductions in RDI after treatment (38.9-10.8 and 3.5-2.0, respectively). The prevalence of moderate to severe OSA was 88% (21/24) in patients with MPS. The overnight polysomnography will help to determine the abnormalities of breathing during sleep more precisely and urge the clinicians to take necessary action for patients with severe manifestations.
Copyright © 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20717914     DOI: 10.1002/ppul.21309

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  19 in total

1.  Obstructive sleep apnea and craniofacial appearance in MPS type I-Hurler children after hematopoietic stem cell transplantation.

Authors:  Till Koehne; Sarah Müller-Stöver; Anja Köhn; Katharina Stumpfe; Susanne Lezius; Carmen Schmid; Zoltan Lukacs; Bärbel Kahl-Nieke; Nicole Muschol
Journal:  Sleep Breath       Date:  2019-07-22       Impact factor: 2.816

2.  Home sleep study characteristics in patients with mucopolysaccharidosis.

Authors:  Çiğdem Seher Kasapkara; Leyla Tümer; Ayşe Tana Aslan; Alev Hasanoğlu; Fatih Süheyl Ezgü; Aynur Küçükçongar; Zeynep Tunca; Oğuz Köktürk
Journal:  Sleep Breath       Date:  2013-05-22       Impact factor: 2.816

3.  Relationship of sleep to pulmonary function in mucopolysaccharidosis II.

Authors:  William I Wooten; Joseph Muenzer; Bradley V Vaughn; Marianne S Muhlebach
Journal:  J Pediatr       Date:  2013-01-08       Impact factor: 4.406

4.  Prevalence of obstructive sleep apnea in patients with mucopolysaccharidosis types I, II, and VI in a reference center.

Authors:  Gustavo A Moreira; Sandra O Kyosen; Camilla L Patti; Ana Maria Martins; Sergio Tufik
Journal:  Sleep Breath       Date:  2014-04-05       Impact factor: 2.816

Review 5.  Sleep-disordered breathing in paediatric setting: existing and upcoming of the genetic disorders.

Authors:  Marco Zaffanello; Franco Antoniazzi; Laura Tenero; Luana Nosetti; Michele Piazza; Giorgio Piacentini
Journal:  Ann Transl Med       Date:  2018-09

6.  Sleep disordered breathing in mucopolysaccharidosis I: a multivariate analysis of patient, therapeutic and metabolic correlators modifying long term clinical outcome.

Authors:  Abhijit Ricky Pal; Eveline J Langereis; Muhammad A Saif; Jean Mercer; Heather J Church; Karen L Tylee; Robert F Wynn; Frits A Wijburg; Simon A Jones; Iain A Bruce; Brian W Bigger
Journal:  Orphanet J Rare Dis       Date:  2015-04-10       Impact factor: 4.123

7.  Assessment of sleep in children with mucopolysaccharidosis type III.

Authors:  Louise Victoria Mahon; Michelle Lomax; Sheena Grant; Elaine Cross; Dougal Julian Hare; James Ed Wraith; Simon Jones; Brian Bigger; Kia Langford-Smith; Maria Canal
Journal:  PLoS One       Date:  2014-02-04       Impact factor: 3.240

Review 8.  Respiratory and sleep disorders in mucopolysaccharidosis.

Authors:  Kenneth I Berger; Simone C Fagondes; Roberto Giugliani; Karen A Hardy; Kuo Sheng Lee; Ciarán McArdle; Maurizio Scarpa; Martin J Tobin; Susan A Ward; David M Rapoport
Journal:  J Inherit Metab Dis       Date:  2012-11-15       Impact factor: 4.982

9.  Actigraphic investigation of circadian rhythm functioning and activity levels in children with mucopolysaccharidosis type III (Sanfilippo syndrome).

Authors:  Rachel A Mumford; Louise V Mahon; Simon Jones; Brian Bigger; Maria Canal; Dougal Julian Hare
Journal:  J Neurodev Disord       Date:  2015-09-01       Impact factor: 4.025

10.  Natural history and clinical assessment of Taiwanese patients with mucopolysaccharidosis IVA.

Authors:  Hsiang-Yu Lin; Chih-Kuang Chuang; Ming-Ren Chen; Pao Chin Chiu; Yu-Yuan Ke; Dau-Ming Niu; Fuu-Jen Tsai; Wuh-Liang Hwu; Ju-Li Lin; Shuan-Pei Lin
Journal:  Orphanet J Rare Dis       Date:  2014-02-10       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.